Assessing understanding of individual risk and symptoms of progressive multifocal leukoencephalopathy in patients prescribed natalizumab for multiple sclerosis.

Rath, Louise; Vijiaratnam, Nirosen; Skibina, Olga

Rath, Louise; Vijiaratnam, Nirosen; Skibina, Olga.

Affiliation

Rath L; Neurology Department, Alfred Health, Melbourne, Victoria, Australia.
Vijiaratnam N; Neurology Department, Alfred Health, Melbourne, Victoria, Australia.
Skibina O; Neurology Department, Alfred Health, Melbourne, Victoria, Australia.

Intern Med J ; 47(2): 194-199, 2017 Feb.

Article in En | MEDLINE | ID: mdl-27862809

Subject(s)

Health Knowledge, Attitudes, Practice; Immunologic Factors/adverse effects; Leukoencephalopathy, Progressive Multifocal/epidemiology; Multiple Sclerosis, Relapsing-Remitting/drug therapy; Natalizumab/adverse effects; Patient Education as Topic; Adult; Australia; Cross-Sectional Studies; Early Diagnosis; Female; Humans; Leukoencephalopathy, Progressive Multifocal/chemically induced; Male; Middle Aged; Patient Participation; Risk Assessment; Surveys and Questionnaires; Treatment Outcome; Young Adult

Key words

early detection; multiple sclerosis; natalizumab; patient education; patient engagement; progressive multifocal leukoencephalopathy

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Health Knowledge, Attitudes, Practice / Patient Education as Topic / Leukoencephalopathy, Progressive Multifocal / Multiple Sclerosis, Relapsing-Remitting / Natalizumab / Immunologic Factors Type of study: Diagnostic_studies / Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies / Screening_studies Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Oceania Language: En Year: 2017 Type: Article

Fulltext

XML

PubMed Links

Search on Google